fda approves first oral glp-1 obesity drug august 21 2025 The approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication FDA approves first GLP-1 pill
Description
The findings, presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey, come from a large real-world analysis led by Professor John Wilding of the University of Liverpool in the UK
The estimated mean weight loss was 7.03 kg in the placebo group, 11.19 kg in the exercise group, 13.74 kg in the liraglutide group, and 16.88 kg in the combination group
Furthermore, the number of neuron-derived orphan receptor 1 (NOR1) which can modulate VSMC proliferation, is decreased by GLP-1RAs in a dose-dependent manner in mice [121]
doi: 10.1161/CIRCULATIONAHA.124.067676
Because obesity is a chronic disease, many patients end up discovering that GLP-1 treatment is not really a short-term intervention
All of these products are of uncompromising quality
